EgriftaAccording to the the National Center for Biotechnology Information, Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. The prevalence of NAFLD in the general population of Western countries is 20-30%. About 2-3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and hepatocarcinoma.
In US the population is about 325 000 000. It means if I’m right that between 65M and 100M persons have NAFLD. Among this population between 6,5M and 10M have NASH.
In may, TH announced that the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) in the United States has awarded a grant to the Massachusetts General Hospital to conduct a study using EGRIFTA® in non-HIV patients suffering Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatosis Hepatosis (NAFLD-NASH).
My question: If the study shows good result for Egrifta, is it possible that Egrifta become the number one seller for TH? And let’s say that Trogarzo will be a great success. Is this what TH is expecting to be one of the big pharma company in Canada?
NCBI link:
https://www.ncbi.nlm.nih.gov/pubmed/20460905